Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. 

MLN2238 is also available as the more stable citrate prodrug MLN9708 (Axon 2557).

KEYWORDS: MLN2238 | supplier | Proteasome inhibitor | Ixazomib | MLN-2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708